The firm, which specialises in commercialising public and corporate research, has closed its largest fund to date.

The mental health benefits platform, which counts Providence Health and Services as an investor, doubled its valuation to $2.3m in the series E round.

Main Street Advisors has invested $9m in the plant-based formula provider through a round already backed by Kaiser Permanente Ventures.

Harvard-founded Nuvalent lured funding from Deerfield to debut with two assets devoted to overcoming kinase-driven resistance to non-small cell lung cancer.

SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.

The cancer drug developer's $12.8m seed round included Eli Lilly, and Lilly New Ventures' Brad Robling is a board observer.

Co-founded by MIT and Memorial Sloan Kettering researchers, Auron Therapeutics has collected $12.8m in a seed round that featured Eli Lilly.

The corporate-backed Cardeation Capital took part in a round for the medical device developer that was led by an unnamed medical technology provider.

Clerkie, Ketos, MedHaul, Perch, Shift, Superpedestrian and Vyv have all received funding from the banking group’s $200m Impact Fund.

MemorialCare Innovation Fund, Rex Ventures and Orlando Health Ventures are set to exit data management software provider Phynd.